Resalis Wants to Treat Obesity Without Appetite Suppression. Its First Human Data Is a Start.

On 5 November, Resalis Therapeutics published three pages of first-in-human data from a trial that began two years earlier in a Dutch clinical unit. The headline was modest: an experimental RNA drug was safe in 48 healthy volunteers. No severe adverse events. Side effects that faded. That is the kind of release that usually vanishes into a pipeline slide.

The detail underneath is more interesting. RES-010 is not an appetite drug. It is an antisense oligonucleotide built to block microRNA-22, a short regulatory RNA that helps control lipid storage and energy use. Resalis says blocking it pushes the body toward burning fat and, in animals, toward converting white fat into the more metabolically active brown kind.

That puts the Torino company on a different road from the GLP-1 class that rebuilt the obesity market. Those drugs work largely by reducing appetite. Resalis is arguing that the next gain comes from changing what the body does with energy, and from preserving muscle while fat comes off.

The thesis is worth testing. It is also early, small, and mostly company-reported. The distance between a safe first dose in healthy volunteers and a durable obesity treatment is where most metabolic programs go to die.

A different lever, and a long shadow

Resalis was founded in 2021 around non-coding RNA and lipid metabolism. Its lead asset, RES-010, is an antisense oligonucleotide aimed at miR-22. In the company's framing, inhibiting miR-22 restores control of lipid biosynthesis, raises energy expenditure, and shifts adipose tissue toward a browner, more thermogenic state.

Preclinical work is the foundation of that claim. Resalis says RES-010 produced fat-selective weight loss in mice and non-human primates while preserving lean mass. Those are the right endpoints to chase. They are also the easiest to produce in a controlled animal study and the hardest to reproduce in people with years of metabolic damage.

Torino is not the only place betting on this idea. RNA medicines have spent a decade proving they can silence genes in the liver. The liver is reachable. Fat tissue, muscle, and the central regulation of energy balance are not.

What 48 healthy volunteers can and cannot tell you

The Phase 1a study was a double-blind, randomised, placebo-controlled, single-ascending-dose trial. It enrolled 48 healthy participants of normal body weight and gave them incremental single doses of RES-010. The European trial registry lists the sponsor as Resalis Therapeutics S.r.l., the site in the Netherlands, and the age range at 18 to 64.¹

Topline results describe a favourable safety and tolerability profile. There were no severe adverse events. Reported side effects were transient, manageable, and consistent with the antisense class, according to the company.

Pharmacodynamics is the more consequential part. Resalis reports associations between weight change, baseline body mass index, and free fatty acid levels. The weight-loss signal was stronger in participants with higher baseline adiposity. That is a hint, not a result. The study was not powered to measure fat loss, and normal-weight volunteers are a poor test of an obesity drug.

“In this single-ascending-dose study, we observed no severe adverse events, and the side effects reported were transient, manageable, and in line with the drug class,” said Diana Røpcke, Resalis' chief medical officer, in the release.

That is a clean safety read for a first-in-human study. It is not evidence that the drug changes body composition. The company's own language is careful on that point: the obesity signal is described as early, and the Phase 1b trial in overweight and moderately obese participants is still running in Australia.

The part the release leaves open

Delivery is the unresolved engineering problem in RNA obesity drugs. Most approved oligonucleotides ride a GalNAc conjugate into liver cells. That works beautifully for liver targets and poorly for adipose tissue, which is exactly where a fat-selective drug needs to act.

Resalis has not disclosed how RES-010 reaches the relevant tissue, how long the effect lasts after dosing stops, or whether the effect depends on continued administration. Those questions decide whether the platform is a treatment or a chronic injection.

The clinical history of microRNA inhibition is a caution. In 2026, the HF-REVERT trial tested CDR132L, an antisense inhibitor of microRNA-132, in 280 patients after myocardial infarction. Plasma microRNA-132 fell in a dose-dependent way, confirming target engagement. The primary endpoint of left ventricular volume did not improve significantly.

Engaging the target and changing the disease are different achievements. Resalis will have to show the second one.

Weight loss alone is not enough to redefine obesity treatment. The real challenge is achieving meaningful fat loss while preserving metabolic health and maintaining the benefits over time, including after treatment ends.— Alessandro Toniolo, chief executive, Resalis Therapeutics

The competitive lane is crowded and narrowing. In 2026, GSK licensed SiranBio's ALK7-targeting siRNA in a deal worth up to $1.005 billion; the asset had entered Phase 1 in roughly 40 overweight or obese participants. Moonwalk raised $70 million for RNAi obesity work. Arrowhead has reported early clinical activity for RNA programs aimed at hepatic and adipose pathways. As we wrote in November, T-Therapeutics raised $133M to put TCR bispecifics in the clinic — the same appetite for clinical proof, in a different modality.

Liver-adjacent mechanisms are further along. A drug that acts on fat tissue directly, without appetite suppression, would be genuinely differentiated. It would also be harder to deliver.

The muscle question is the commercial question

Obesity drugs are now judged on more than the number on a scale. Clinicians and payers have started asking what proportion of the weight lost is fat and what proportion is lean tissue. Rapid weight loss on appetite-suppressing drugs often takes muscle with it, and muscle matters for mobility, glucose handling, and whether the weight stays off.

That is the opening Resalis is trying to exploit. If RES-010 can show fat-selective loss with lean mass preserved, it would offer something the current class struggles to deliver. It would also fit a reimbursement logic that is shifting from “how much weight” to “what kind of weight.”

The commercial logic only works if the effect is durable. A drug that requires continuous dosing to hold body composition would compete on convenience against established injectables and newcomers alike. A drug that holds its effect after a finite course would be a different product category.

Resalis has not published the dosing duration it intends to test in later trials, or the follow-up period it will use to measure rebound. Those choices will say more about the program's ambition than any early weight signal. For now, the Phase 1a data supports a safety claim, and the rest is a hypothesis with a date attached.

What would make this real

The Phase 1b readout, expected in the first half of 2027, is the next gate. It uses multiple ascending doses in healthy, overweight, and moderately obese people without obesity-related comorbidities. The company will look at safety, pharmacokinetics, and pharmacodynamics over a longer exposure window.

The endpoints that matter are unglamorous. Does fat mass fall? Does lean mass hold? Do free fatty acids and other metabolic markers move in the right direction? Does the effect persist after the last dose?

Nothing in the Phase 1a release answers those questions. That is normal for this stage. It also means the market's reaction should stay small until the Phase 1b data arrives.

¹ The EU registry lists the Phase 1 trial as ending 21 April 2026; Resalis published Phase 1a topline on 5 November 2026, after database lock and analysis.